No connection

Search Results

NXGL vs QUCY

NXGL
NEXGEL, Inc.
BEARISH
Price
$0.76
Market Cap
$6.4M
Sector
Healthcare
AI Confidence
95%
QUCY
Mainz Biomed N.V.
BEARISH
Price
$0.49
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NXGL
--
QUCY
--
Forward P/E
NXGL
3.29
QUCY
--
P/B Ratio
NXGL
1.38
QUCY
7.38
P/S Ratio
NXGL
0.56
QUCY
11.35
EV/EBITDA
NXGL
-3.31
QUCY
-0.6

Profitability

Gross Margin
NXGL
39.48%
QUCY
72.58%
Operating Margin
NXGL
-43.42%
QUCY
-2159.86%
Profit Margin
NXGL
-26.27%
QUCY
0.0%
ROE
NXGL
-52.74%
QUCY
-488.32%
ROA
NXGL
-19.54%
QUCY
-89.61%

Growth

Revenue Growth
NXGL
-8.1%
QUCY
-32.9%
Earnings Growth
NXGL
--
QUCY
--

Financial Health

Debt/Equity
NXGL
0.63
QUCY
4.01
Current Ratio
NXGL
1.47
QUCY
0.5
Quick Ratio
NXGL
0.34
QUCY
0.27

Dividends

Dividend Yield
NXGL
--
QUCY
--
Payout Ratio
NXGL
0.0%
QUCY
0.0%

AI Verdict

NXGL BEARISH

NXGL exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company suffers from chronic profitability issues, with negative operating margins (-43.42%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). Revenue is shrinking both YoY and Q/Q, while the stock has plummeted over 73% in the last year. Combined with bearish insider selling by the CEO, the outlook is highly precarious.

Strengths
Positive gross margin of 39.48%
Manageable Debt/Equity ratio of 0.63
Current ratio of 1.47 suggests short-term solvency
Risks
Critical fundamental health (Piotroski 1/9)
Negative revenue growth (-8.10% YoY)
Severe liquidity risk indicated by a low Quick Ratio (0.34)
QUCY BEARISH

QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.

Strengths
Strong Gross Margin (72.58%) indicating product value
Recent trend of beating EPS estimates (3/4 quarters)
Positive Q/Q EPS growth (+38.5%) although still deeply negative
Risks
Severe liquidity risk with a Quick Ratio of 0.27
Extreme operational losses (Operating Margin -2159.86%)
Significant revenue contraction (-32.90% YoY)

Compare Another Pair

NXGL vs QUCY: Head-to-Head Comparison

This page compares NEXGEL, Inc. (NXGL) and Mainz Biomed N.V. (QUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile